1. Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma.
- Author
-
Lin X, Guan T, Xu Y, Li Y, Lin Y, Chen S, Chen Y, Wei X, Li D, Cui Y, Lin Y, Sun P, Guo J, Li C, Gu J, Yang W, Zeng H, and Ma C
- Subjects
- Humans, Animals, Mice, Killer Cells, Natural, B7 Antigens metabolism, Receptors, Chimeric Antigen, Induced Pluripotent Stem Cells, Esophageal Squamous Cell Carcinoma therapy, Esophageal Neoplasms therapy, Esophageal Neoplasms metabolism
- Abstract
Introduction: Chimeric antigen receptor natural killer (CAR-NK) cells have been found to be successful in treating hematologic malignancies and present potential for usage in solid tumors., Methods: In this study, we created CD276-targeted CAR-expressing NK cells from pluripotent stem cells (iPSC CD276-targeted CAR-NK cells) and evaluated their cytotoxicity against esophageal squamous cell carcinoma (ESCC) using patient-specific organoid (PSO) models comprising of both CD276-positive and CD276-negative adjacent epithelium PSO models (normal control PSO, NC PSO) as well as primary culture of ESCC cell models. In addition, in vitro and in vivo models such as KYSE-150 were also examined. iPSC NK cells and NK-free media were used as the CAR-free and NK-free controls, respectively., Results: The positive CD276 staining was specifically detected on the ESCC membrane in 51.43% (54/105) of the patients of all stages, and in 51.35% (38/74) of stages III and IV. The iPS CD276-targeted CAR-NK cells, comparing with the iPS NK cells and the NK-free medium, exhibited specific and significant cytotoxic activity against CD276-positive ESCC PSO rather than CD276-negative NC PSO, and exhibited significant cytotoxicity against CD276-expressing cultured ESCC cells, as well as against CD276-expressing KYSE-150 in vitro and in BNDG mouse xenograft., Discussion: The efficacy of the iPSC CD276-targeted CAR-NK cells demonstrated by their successful treatment of CD276-expressing ESCC in a multitude of pre-clinical models implied that they hold tremendous therapeutic potential for treating patients with CD276-expressing ESCC., Competing Interests: Authors HZ, TG, YLi, YCL were employed by Guangdong Procapzoom Bioscience Inc. Author WY was employed by Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This study received funding from PCZ-SUMC cooperation and research projects. The funder had the following involvement with the study of the efficacy of CD276-targeted CAR NK cells against human esophageal squamous cell carcinoma., (Copyright © 2024 Lin, Guan, Xu, Li, Lin, Chen, Chen, Wei, Li, Cui, Lin, Sun, Guo, Li, Gu, Yang, Zeng and Ma.)
- Published
- 2024
- Full Text
- View/download PDF